BioAdaptives plans reverse stock split after shares balloon 6,530% in 5 years; CEO cites turnaround

BIOADAPTIVES, INC.

Shares outstanding grew from 18.6M (Jan 2020) to 1.23B (June 2024), a 6,530% increase with no revenue growth.
Reverse split intended to lift stock from sub-penny range; ratio and effective date not yet specified.
CEO James Keener (since management change) leading turnaround with new product lines for human and animal health.
Company expects increased revenue and profitability from upcoming product launches through new distribution channels.
Draft letter prematurely published by website contractor error; this press release clarifies the planned reverse split.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.